Skip to main content

Table 1 Clinical profile of patients with B-cell lymphoma of the mediastinum

From: Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma

  CHL, NS (N = 13)PMLBCL (N = 16)p valueGray zone (N = 3)
AgeMedian (Range)26(15–73)30 (19–51)0.17528 (25–52)
SexMale: Female4(30.8%): 9(69.2%)6(37.5%): 10(62.5%)1.0002: 1
Methods of biopsyNeedle: VATS: Open6: 3: 410: 4: 2 0: 0: 3
IPI scoreHigh risk (> 3) or low7(87.5%): 1(12.5%)13(86.7%): 2(13.3%)1.0001: 2
Ann Arbor stageI-II: III-IV8(80.0%): 2(20.0%)10(71.4%): 4(28.5%)1.0001: 2
LDHElevated or not4(57.1%): 3(42.9%)12(80.0%): 3(20.0%)0.3340: 3
ECOG score≥2 or less0: 12(100%)0: 14(100%) 0: 3
Bone marrowInvolved or not1(9.1%): 10(90.9%)2(13.3%): 13(86.7%)1.0000: 3
Bulky diseaseYes or No6(54.5%): 5(45.5%)11(73.3%): 4(26.7%)0.4191: 2
B symptomsYes or No5(55.6%): 4(44.4%)4(28.6%): 10(71.4%)0.3831: 2
Follow-up (months)Median (Range)72 (1–116)14(1–57) 48 (14–84)
 Dead/Alive0: 12(100%)4(26.7%): 11(73.3%)0.1061: 2
ProgressionYes or No0: 12(100%)6(42.9%): 8(57.1%)0.0171: 2
  1. CHL classic Hodgkin lymphoma, NS nodular sclerosis, PMLBCL primary mediastinal diffuse large B-cell lymphoma (DLBCL); Gray, B-cell lymphoma unclassifiable, with features intermediate between DLBCL and classic Hodgkin lymphoma; VATS video-assisted thoracoscopic surgery